RewersM. Why do people with diabetes die too soon? More questions than answers. Diabetes Care, 2008; 31:830–832.
2.
SecrestAM, BeckerDJ, KelseySF, LaPorteRE, OrchardTJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County Type 1 Diabetes Registry. Diabetes Care, 2010; 33:2573–2579.
3.
BuseJB, GinsbergHN, BakrisGL, ClarkNG, CostaF, EckelR, FonsecaV, GersteinHC, GrundyS, NestoRW, PignoneMP, PlutzkyJ, PorteD, RedbergR, StitzelKF, StoneNJ. American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 2007; 115:114–126.
4.
NathanDM, ClearyPA, BacklundJY, GenuthSM, LachinJM, OrchardTJ, RaskinP, ZinmanB. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353:2643–2653.
5.
HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359:1577–1589.
6.
PambiancoG, CostacouT, EllisD, BeckerDJ, KleinR, OrchardTJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes, 2006; 55:1463–1469.
7.
LiuLL, LawrenceJM, DavisC, LieseAD, PettittDJ, PihokerC, DabeleaD, HammanR, WaitzfelderB, KahnHS. SEARCH for Diabetes in Youth Study Group. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes, 2010; 11:4–11.
8.
Ismail-BeigiF, MoghissiE, TiktinM, HirschIB, InzucchiSE, GenuthS. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med, 2011; 154:554–559.
9.
MaahsDM, WadwaRP, BishopF, DanielsSR, RewersM, KlingensmithGJ. Dyslipidemia in youth with diabetes: to treat or not to treat?J Pediatr, 2008; 153:458–465.
10.
BrownleeM, HirschIB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA, 2006; 295:1707–1708.
11.
CerielloA, IhnatMA, ThorpeJE. Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?J Clin Endocrinol Metab, 2009; 94:410–415.
12.
ZoungasS, PatelA, ChalmersJ, de GalanBE, LiQ, BillotL, WoodwardM, NinomiyaT, NealB, MacMahonS, GrobbeeDE, KengneAP, MarreM, HellerS. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med, 2010; 363:1410–1418.
13.
Action to Control Cardiovascular Risk in Diabetes Study Group. GersteinHC, MillerME, ByingtonRP, GoffDCJr, BiggerJT, BuseJB, CushmanWC, GenuthS, Ismail-BeigiF, GrimmRHJr, ProbstfieldJL, Simons-MortonDG, FriedewaldWT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
14.
PeñaAS, CouperJJ, HarringtonJ, GentR, FairchildJ, ThamE, BaghurstP. Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes. Diabetes Technol Ther, 2012; 14:457–462.
15.
TheiladeS, JoergensenC, PerssonF, LajerM, RossingP. Ambulatory tonometric blood pressure measurements in patients with diabetes. Diabetes Technol Ther, 2012; 14:453–456.
16.
SilversteinJ, KlingensmithG, CopelandK, PlotnickL, KaufmanF, LaffelL, DeebL, GreyM, AndersonB, HolzmeisterLA, ClarkN. American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care, 2005; 28:186–212.
17.
McCrindleBW, UrbinaEM, DennisonBA, JacobsonMS, SteinbergerJ, RocchiniAP, HaymanLL, DanielsSR. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation, 2007; 115:1948–1967.
18.
DanielsSR, GreerFR. Lipid screening and cardiovascular health in childhood. Pediatrics, 2008; 122:198–208.
19.
DonaghueKC, ChiarelliF, TrottaD, AllgroveJ, Dahl-JørgensenK. International Society for Pediatric and Adolescent Diabetes: ISPAD Clinical Practice Consensus Guidelines 2006–2007. Microvascular and macrovascular complications. Pediatr Diabetes, 2007; 8:163–170.
20.
McGillHCJr, McMahanCA, MalcomGT, OalmannMC, StrongJP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol, 1995; 15:431–440.
21.
BerensonGS, SrinivasanSR, BaoW, NewmanWP3rd, TracyRE, WattigneyWA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med, 1998; 338:1650–1656.
22.
KershnarAK, DanielsSR, ImperatoreG, PallaSL, PetittiDB, PettittDJ, MarcovinaS, DolanLM, HammanRF, LieseAD, PihokerC, RodriguezBL. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr, 2006; 149:314–319.
23.
SchwabKO, DoerferJ, HeckerW, Grulich-HennJ, WiemannD, KordonouriO, BeyerP, HollRW. DPV Initiative of the German Working Group for Pediatric Diabetology. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV)Diabetes Care, 2006; 29:218–225.
24.
RodriguezBL, DabeleaD, LieseAD, FujimotoW, WaitzfelderB, LiuL, BellR, TaltonJ, SnivelyBM, KershnarA, UrbinaE, DanielsS, ImperatoreG. SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for Diabetes in Youth Study. J Pediatr, 2010; 157:245–251.
25.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. NathanDM, ZinmanB, ClearyPA, GenuthS, MillerR, OrchardTJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005)Arch Intern Med, 2009; 169:1307–1316.
26.
MaahsDM, OgdenLG, DabeleaD, Snell-BergeonJK, DanielsSR, HammanRF, RewersM. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia, 2010; 53:2518–2525.
27.
BulsaraMK, HolmanCD, DavisEA, JonesTW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care, 2004; 27:2293–2298.
28.
DownieE, CraigME, HingS, CusumanoJ, ChanAK, DonaghueKC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care, 2011; 34:2368–2373.
29.
MargeirsdottirHD, LarsenJR, KummernesSJ, BrunborgC, Dahl-JørgensenK. The establishment of a new national network leads to quality improvement in childhood diabetes: implementation of the ISPAD Guidelines. Pediatr Diabetes, 2010; 11:88–95.
30.
SvenssonJ, JohannesenJ, MortensenHB, NordlyS. Improved metabolic outcome in a Danish diabetic paediatric population aged 0–18 yr: results from a nationwide continuous registration. Pediatr Diabetes, 2009; 10:461–467.
31.
RosenbauerJ, DostA, KargesB, HungeleA, StahlA, BächleC, GerstlEM, KastendieckC, HoferSE, HollRW. DPV Initiative and the German BMBF Competence Network Diabetes Mellitus. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care, 2012; 35:80–86.
32.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA, 2003; 290:2159–2167.
33.
PetittiDB, KlingensmithGJ, BellRA. Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr, 2009; 155:668–672.
34.
PavkovME, BennettPH, KnowlerWC, KrakoffJ, SieversML, NelsonRG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA, 2006; 296:421–426.
35.
MaahsDM, DanielsSR. A pediatric perspective: adult problems in kids, new challenges in pediatric diabetes. Pediatr Diabetes, 2007; 8:349–351.
36.
Pinhas-HamielO, ZeitlerP. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet, 2007; 369:1823–1831.
37.
NadeauKJ, MaahsDM, DanielsSR, EckelRH. Childhood obesity and cardiovascular disease: links and prevention strategies. Nat Rev Cardiol, 2011; 8:513–25.
38.
Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT)BMC Pediatr, 2009; 9:79.
39.
TODAY Study Group. ZeitlerP, EpsteinL, GreyM, HirstK, KaufmanF, TamborlaneW, WilfleyD. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes, 2007; 8:74–87.
40.
TruongUT, MaahsDM, DanielsSR. Cardiovascular disease in children and adolescents with diabetes: where are we, and where are we going?Diabetes Technol Ther, 2012; 14,Suppl 1:S11–S21.
41.
CooperWO, Hernandez-DiazS, ArbogastPG, DudleyJA, DyerS, GideonPS, HallK, RayWA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med, 2006; 354:2443–2451.
